Evidence map›Paper›PMID 41776391›Full record

ArticleBMC microbiology2026

Predicting pyrazinamide resistance in Mycobacterium tuberculosis using a graph convolutional network.

Dylan Dissanayake, Viktoria Brunner, Dylan Adlard, Joseph A Morrone, Philip W Fowler

Abstract read
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dylan DissanayakeNuffield Department of Medicine, University of Oxford, Oxford, UK.
Viktoria BrunnerNuffield Department of Medicine, University of Oxford, Oxford, UK.
Dylan AdlardNuffield Department of Medicine, University of Oxford, Oxford, UK.
Joseph A MorroneIBM TJ Watson Research Center, IBM Research, 1101 Kitchawan Rd., Yorktown Heights, NY, 10598, USA.
Philip W FowlerNuffield Department of Medicine, University of Oxford, Oxford, UK. philip.fowler@ndm.ox.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/T008784/1Engineering and Physical Sciences Research Council EP/S024093/1National Institute for Health and Care Research NIHR207397
6 · The paper itself

Abstract

backgroundPyrazinamide is an important first-line antibiotic for treating tuberculosis, with resistance primarily driven by mutations in the pncA gene. Traditional machine learning models are able to predict pyrazinamide resistance with some success but are limited in their ability to incorporate 3-dimensional protein structural information. Graph neural networks offer the potential to integrate protein structure and residue-level features to better predict the impact of mutations on drug resistance.

resultsWe trained a graph convolutional network on PncA variants containing missense mutations and evaluated its ability to classify resistance to pyrazinamide. Each PncA variant was represented as an amino acid-level graph, with edges calculated from 3-dimensional spatial proximity, and node features derived from chemical properties and mutation meta-predictors. We used AlphaFold2 to generate predicted structures of the PncA variants, which we used to create the protein graphs. The predicted structures of resistant PncA variants showed greater deviation from the wild-type structure compared to susceptible variants. Our model achieved an F1 score of 81.6%, sensitivity of 81.6% and specificity of 80.4% on the test set and either matched or exceeded the performance of a published set of traditional machine learning models. We show that both structural graph connectivity and node features contribute significantly to model performance. Furthermore, we employ additional train/test dataset splits to demonstrate the GCN’s ability to generalise and predict resistance in samples with mutations in unseen positions and structural regions.

conclusionsOur study demonstrates that graph-based deep learning can leverage protein structure and biochemical features to accurately predict antimicrobial resistance, despite being trained on a small dataset with little variation. We present this as a proof-of-concept for these methods to be applied to resistance phenotype prediction in more genetically diverse pathogens to predict the more complex observed patterns of antimicrobial resistance.

Indexed as

Antitubercular AgentsDrug Resistance, BacterialMycobacterium tuberculosisPyrazinamideAmidohydrolasesGraph Neural NetworksMachine LearningMutation, MissenseAmidohydrolasesAntitubercular AgentsPncA protein, Mycobacterium tuberculosisPyrazinamideAntimicrobial resistanceDeep learningGraph convolutional networksGraph neural networksMachine learningPncAPyrazinamideTuberculosis

Identifiers

PMID41776391
PMCPMC13063690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.